Skip to main content
. 2017 Oct 19;12:3065–3073. doi: 10.2147/COPD.S143334

Table 3.

Model base-case results

Parameter Aerobika* device No PEP/OPEP therapy
Total direct medical cost $7,829 $8,382
Total exacerbations (average #/patient) 0.77 0.83
Cost savings $553/patient
Number of exacerbations avoided 0.06 (ie, six per 100 patients)
ICER Aerobika* device is the dominant strategy

Abbreviations: ICER, incremental cost-effectiveness ratio; OPEP, oscillating positive expiratory pressure; PEP, positive expiratory pressure.